Justin Schweitzer, OD, FAAO

Earlier this year, Aurion’s cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the management of bullous keratopathy, marking the first regulatory approval in the world for an allogeneic cell therapy to manage corneal endothelial disease.

At AAOpt, Justin Schweitzer, OD, FAAO, and Selina McGee, OD, FAAO, Dipl ABO, discuss the intersection of dry eye and glaucoma.

Justin Schweitzer, OD, FAAO, discusses his talk, "Current trends in keratoconus management," at Vision Expo West 2023 in Las Vegas, Nevada.

Justin Schweitzer, OD, FAAO, and Nathan Lighthizer, OD, provide key takeaways from their 2023 AOA presentation, "Beyond drops: Surgical considerations in glaucoma," which they will give alongside Walter Whitley, OD, MBA, FAAO.

Today at the IKA Keratoconus Symposium, Justin Schweitzer, OD, FAAO, presented on establishing the keratoconus diagnosis alongside Kourtney Houser, MD.

Optometrists must identify and mitigate complications for this patient base.

Experts answer clinicians’ common questions on treating patients.

Justin Schweitzer, OD, shares key highlights from his presentation titled, "The OD's Role in the Management of MIGS in 2022," where he explores earlier intervention for glaucoma patients.

Reducing the burden of drops can improve patients’ QOL and prevent progression of glaucoma.

Know the facts, not misinformation, about slowing or halting disease progression

Find out the latest on technologies, techniques, and treatments